Cardinal Health (NYSE:CAH) has received a consensus rating of “Hold” from the twenty brokerages that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $74.61.
Several analysts recently issued reports on CAH shares. Evercore ISI started coverage on shares of Cardinal Health in a research report on Thursday, January 4th. They issued an “in-line” rating and a $67.00 price target for the company. TheStreet raised shares of Cardinal Health from a “c+” rating to a “b-” rating in a research report on Tuesday, March 13th. Barclays started coverage on shares of Cardinal Health in a research report on Thursday, March 8th. They issued an “equal weight” rating and a $74.00 price target for the company. Zacks Investment Research raised shares of Cardinal Health from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a research report on Monday, January 29th. Finally, Argus raised shares of Cardinal Health from a “hold” rating to a “buy” rating and set a $85.00 price target for the company in a research report on Monday, April 2nd.
Shares of CAH stock traded down $0.24 during trading hours on Friday, hitting $62.07. 2,696,522 shares of the company were exchanged, compared to its average volume of 2,532,018. The company has a market cap of $19,533.86, a price-to-earnings ratio of 11.49, a price-to-earnings-growth ratio of 1.42 and a beta of 1.07. Cardinal Health has a fifty-two week low of $54.66 and a fifty-two week high of $80.37. The company has a quick ratio of 0.57, a current ratio of 1.09 and a debt-to-equity ratio of 1.19.
Cardinal Health (NYSE:CAH) last announced its quarterly earnings data on Thursday, February 8th. The company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.14 by $0.17. The company had revenue of $35.19 billion during the quarter, compared to the consensus estimate of $34.63 billion. Cardinal Health had a net margin of 1.37% and a return on equity of 24.81%. The company’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 EPS. analysts anticipate that Cardinal Health will post 5.41 earnings per share for the current year.
Cardinal Health declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 8th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which was paid on Sunday, April 15th. Shareholders of record on Monday, April 2nd were paid a dividend of $0.4624 per share. This represents a $1.85 annualized dividend and a yield of 2.98%. The ex-dividend date of this dividend was Thursday, March 29th. Cardinal Health’s dividend payout ratio (DPR) is presently 34.26%.
In other Cardinal Health news, CEO Jon L. Giacomin sold 7,995 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $68.78, for a total transaction of $549,896.10. Following the transaction, the chief executive officer now directly owns 63,043 shares in the company, valued at approximately $4,336,097.54. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael C. Kaufmann sold 18,586 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $73.90, for a total value of $1,373,505.40. Following the transaction, the chief executive officer now owns 211,849 shares in the company, valued at $15,655,641.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,113 shares of company stock worth $3,815,073. Company insiders own 0.97% of the company’s stock.
Large investors have recently modified their holdings of the business. Janus Henderson Group PLC lifted its stake in Cardinal Health by 77.8% during the 3rd quarter. Janus Henderson Group PLC now owns 108,930 shares of the company’s stock valued at $7,291,000 after acquiring an additional 47,669 shares in the last quarter. New Mexico Educational Retirement Board raised its stake in shares of Cardinal Health by 3.7% during the 4th quarter. New Mexico Educational Retirement Board now owns 30,454 shares of the company’s stock worth $1,866,000 after purchasing an additional 1,100 shares during the period. Wells Fargo & Company MN raised its stake in shares of Cardinal Health by 28.7% during the 4th quarter. Wells Fargo & Company MN now owns 1,318,252 shares of the company’s stock worth $80,768,000 after purchasing an additional 293,863 shares during the period. Vident Investment Advisory LLC bought a new stake in shares of Cardinal Health during the 4th quarter worth $579,000. Finally, Toronto Dominion Bank raised its stake in shares of Cardinal Health by 13.0% during the 4th quarter. Toronto Dominion Bank now owns 135,627 shares of the company’s stock worth $8,310,000 after purchasing an additional 15,613 shares during the period. Institutional investors and hedge funds own 90.02% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Cardinal Health (CAH) Receives Consensus Rating of “Hold” from Analysts” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/22/cardinal-health-cah-receives-consensus-rating-of-hold-from-analysts.html.
About Cardinal Health
Cardinal Health, Inc operates as an integrated healthcare services and products company worldwide. The company's Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare, and consumer products to retailers, hospitals, and other healthcare providers.
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.